Biotech company Geron Corp. will conduct a human clinical trial on patients with spinal cord injuries, using a federally approved line of embryonic stem cells. The approval is the first of its kind in the world. Stem cell experts discuss the significance of the decision.
Thomas Okarma, president and CEO, Geron Corporation, Menlo Park, Calif.
Sean J. Morrison, director, University of Michigan Center for Stem Cell Biology, Ann Arbor, Mich.